Free Trial

Ampio Pharmaceuticals Q2 2023 Earnings Report

Ampio Pharmaceuticals logo
$0.0021 0.00 (0.00%)
As of 02/21/2025

Ampio Pharmaceuticals EPS Results

Actual EPS
-$1.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ampio Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ampio Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Ampio Pharmaceuticals Earnings Headlines

Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated at StockNews.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
Ampio Pharmaceuticals, Inc. (AMPE)
See More Ampio Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ampio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ampio Pharmaceuticals and other key companies, straight to your email.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

View Ampio Pharmaceuticals Profile

More Earnings Resources from MarketBeat